 |
30 Diseases |  |
10 Trials |
|
10 Trials |  |
301 News |  |
| «12345 |
- Dojolvi (triheptanoin) / Ultragenyx
Enrollment closed, Trial primary completion date: Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder (clinicaltrials.gov) - Sep 30, 2014
P2, N=32, Active, not recruiting, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015
- ||||| Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies (clinicaltrials.gov) - Aug 12, 2014
P2, N=100, Not yet recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
- Dojolvi (triheptanoin) / Ultragenyx
New P3 trial: Triheptanoin Treatment Trial for Patients With Long-chain Fatty Acid Beta-oxidation Defects (clinicaltrials.gov) - Jul 30, 2014
P3, N=0, Withdrawn, Sponsor: Maria Luz Couce Pico
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment change: Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Jun 27, 2014
P2, N=40, Recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015 N=50 --> 40
- Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder (clinicaltrials.gov) - Jun 19, 2014
P2, N=32, Recruiting, Sponsor: Oregon Health and Science University
N=50 --> 40 Trial primary completion date: May 2014 --> Dec 2014
- Dojolvi (triheptanoin) / Ultragenyx
Trial primary completion date: Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome (clinicaltrials.gov) - May 25, 2014
P2, N=3, Recruiting, Sponsor: University of British Columbia
Trial primary completion date: May 2014 --> Dec 2014 Trial primary completion date: Jul 2014 --> Jul 2015
- Dojolvi (triheptanoin) / Ultragenyx
Trial completion date: Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome (clinicaltrials.gov) - May 25, 2014
P2, N=3, Recruiting, Sponsor: University of British Columbia
Trial primary completion date: Jul 2014 --> Jul 2015 Trial completion date: Sep 2014 --> Sep 2015
- Dojolvi (triheptanoin) / Ultragenyx
Enrollment open: Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome (clinicaltrials.gov) - May 25, 2014
P2, N=3, Recruiting, Sponsor: University of British Columbia
Trial completion date: Sep 2014 --> Sep 2015 Not yet recruiting --> Recruiting
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment change: A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) (clinicaltrials.gov) - Feb 9, 2014
P2, N=30, Recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
Not yet recruiting --> Recruiting N=20 --> 30
- Dojolvi (triheptanoin) / Ultragenyx
Enrollment open: Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Feb 3, 2014
P2, N=50, Recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
N=20 --> 30 Not yet recruiting --> Recruiting
- | Dojolvi (triheptanoin) / Ultragenyx
New P2 trial, Journal: GLUT1DS: An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (clinicaltrials.gov) - Jan 12, 2014
P2, N=50, Recruiting, Sponsor: Adrian Lacy
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment open: GLUT1DS: An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (clinicaltrials.gov) - Jan 12, 2014
P2, N=50, Recruiting, Sponsor: Adrian Lacy
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment open: GLUT-HEP: Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS (clinicaltrials.gov) - Jan 8, 2014
P2, N=20, Recruiting, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Dojolvi (triheptanoin) / Ultragenyx
New P1/2 trial: Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D) (clinicaltrials.gov) - Dec 25, 2013
P1/2, N=50, Not yet recruiting, Sponsor: Juan Pascual
- Dojolvi (triheptanoin) / Ultragenyx
New P1 trial: Post Study Continuation of C7 for G1D (clinicaltrials.gov) - Dec 19, 2013
P1, N=0, Available, Sponsor: Juan Pascual
- Dojolvi (triheptanoin) / Ultragenyx
New P1 trial: Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) (clinicaltrials.gov) - Dec 19, 2013
P1, N=14, Active, not recruiting, Sponsor: Juan Pascual
- | Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: GLUT-HEP: Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS (clinicaltrials.gov) - Dec 16, 2013
P2, N=20, Recruiting, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
- Dojolvi (triheptanoin) / Ultragenyx
Trial completion: Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease (clinicaltrials.gov) - Dec 16, 2013
P2, N=10, Completed, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Not yet recruiting --> Recruiting Recruiting --> Completed
- Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome (clinicaltrials.gov) - Dec 2, 2013
P2, N=3, Not yet recruiting, Sponsor: Sylvia Stockler
- Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) (clinicaltrials.gov) - Nov 21, 2013
P2, N=50, Recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
- | Dojolvi (triheptanoin) / Ultragenyx
Enrollment open: A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) (clinicaltrials.gov) - Sep 15, 2013
P2, N=30, Recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) (clinicaltrials.gov) - Jun 23, 2013
P2, N=30, Recruiting, Sponsor: Ultragenyx Pharmaceutical Inc
- Dojolvi (triheptanoin) / Ultragenyx
New P2 trial: Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease (clinicaltrials.gov) - Jun 18, 2013
P2, N=10, Completed, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
- Dojolvi (triheptanoin) / Ultragenyx
New P1/2 trial: ACETO-TCA: Study of the Acute Effects of Triheptanoin in Heart Failure (clinicaltrials.gov) - Feb 7, 2013
P1/2, N=24, Recruiting, Sponsor: University of Texas Southwestern Medical Center